ProCE Banner Activity

SWOG S1505: Phase II Study of Perioperative CT With mFOLFIRINOX vs Gemcitabine/nab-Paclitaxel in Resectable Pancreatic Ductal Adenocarcinoma

Slideset Download
Conference Coverage
The S1505 trial failed to meet primary endpoint of 2-year OS rate ≥ 58% with perioperative mFOLFIRINOX or gemcitabine/nab-paclitaxel.

Released: June 04, 2020

Expiration: June 03, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono